The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2017

Filed:

Nov. 19, 2015
Applicants:

Janssen Pharmaceuticals, Inc., Titusville, NJ (US);

Addex Pharma S.a., Plan-les-Ouates, CH;

Inventors:
Assignees:

Janssen Pharmaceuticals. Inc., Titusville, NJ (US);

Addex Pharma SA, Geneva, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5375 (2006.01); A61K 31/5377 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); C07D 471/04 (2006.01); C07D 519/00 (2006.01); A61K 45/06 (2006.01); A61K 31/4545 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 9/20 (2006.01); A61K 31/438 (2006.01); A61K 31/506 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 9/0019 (2013.01); A61K 9/0095 (2013.01); A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61K 9/2059 (2013.01); A61K 31/437 (2013.01); A61K 31/438 (2013.01); A61K 31/4545 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 471/04 (2013.01); C07D 519/00 (2013.01);
Abstract

The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ('mGluR2'), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.


Find Patent Forward Citations

Loading…